Last reviewed 2026-04-19 · How we verify

Dextrose intraarticularly administered

Universidad Nacional de Rosario · Phase 2 active Small molecule

Dextrose intraarticularly administered is a Small molecule drug developed by Universidad Nacional de Rosario. It is currently in Phase 2 development. Also known as: Glucose.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Dextrose intraarticularly administered
Also known as	Glucose
Sponsor	Universidad Nacional de Rosario
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dextrose intraarticularly administered CI brief — competitive landscape report
Dextrose intraarticularly administered updates RSS · CI watch RSS
Universidad Nacional de Rosario portfolio CI

Frequently asked questions about Dextrose intraarticularly administered

What is Dextrose intraarticularly administered?

Dextrose intraarticularly administered is a Small molecule drug developed by Universidad Nacional de Rosario.

Who makes Dextrose intraarticularly administered?

Dextrose intraarticularly administered is developed by Universidad Nacional de Rosario (see full Universidad Nacional de Rosario pipeline at /company/universidad-nacional-de-rosario).

Is Dextrose intraarticularly administered also known as anything else?

Dextrose intraarticularly administered is also known as Glucose.

What development phase is Dextrose intraarticularly administered in?

Dextrose intraarticularly administered is in Phase 2.

Manufacturer: Universidad Nacional de Rosario — full pipeline
Also known as: Glucose

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing